Dysregulated mesenchymal PDGFR-β drives kidney fibrosis.

Buhl EM, Djudjaj S, Klinkhammer BM, Ermert K, Puelles VG, Lindenmeyer MT, Cohen CD, He C, Borkham-Kamphorst E, Weiskirchen R, Denecke B, Trairatphisan P, Saez-Rodriguez J, Huber TB, Olson LE, Floege J, Boor P

Open source

DOI
10.15252/emmm.201911021
Published
2020 Mar 6
Container
EMBO molecular medicine
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.15252/emmm.201911021,
  title = {Dysregulated mesenchymal PDGFR-β drives kidney fibrosis.},
  author = {Buhl EM and Djudjaj S and Klinkhammer BM and Ermert K and Puelles VG and Lindenmeyer MT and Cohen CD and He C and Borkham-Kamphorst E and Weiskirchen R and Denecke B and Trairatphisan P and Saez-Rodriguez J and Huber TB and Olson LE and Floege J and Boor P},
  year = {2020},
  journal = {EMBO molecular medicine},
  doi = {10.15252/emmm.201911021},
  url = {https://doi.org/10.15252/emmm.201911021}
}

RIS

TY  - JOUR
TI  - Dysregulated mesenchymal PDGFR-β drives kidney fibrosis.
AU  - Buhl EM
AU  - Djudjaj S
AU  - Klinkhammer BM
AU  - Ermert K
AU  - Puelles VG
AU  - Lindenmeyer MT
AU  - Cohen CD
AU  - He C
AU  - Borkham-Kamphorst E
AU  - Weiskirchen R
AU  - Denecke B
AU  - Trairatphisan P
AU  - Saez-Rodriguez J
AU  - Huber TB
AU  - Olson LE
AU  - Floege J
AU  - Boor P
PY  - 2020
JO  - EMBO molecular medicine
DO  - 10.15252/emmm.201911021
UR  - https://doi.org/10.15252/emmm.201911021
ER  - 

APA

EM, B., S, D., BM, K., K, E., VG, P., MT, L., CD, C., C, H., E, B., R, W., B, D., P, T., J, S., TB, H., LE, O., J, F., & P, B. (2020). Dysregulated mesenchymal PDGFR-β drives kidney fibrosis.. EMBO molecular medicine. https://doi.org/10.15252/emmm.201911021

Source records